Verona Pharma PLC Notice of Results

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                               Notice of Results 
 
27 August 2015, Cardiff - Verona Pharma plc (AIM: VRP), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
expects to announce its interim results for the six months ended 30 June 2015 
on Tuesday 8 September 2015. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                          Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive 
Officer 
 
FTI Consulting                             Tel: +44 (0)20 3727 1000 
Julia Phillips / Simon Conway 
 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the Cystic Fibrosis Trust. 
 
 
 
END

(END) Dow Jones Newswires

August 27, 2015 02:00 ET (06:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024